Dear editor,

Neovascular age-related macular degeneration (nAMD) is a major cause of vision loss worldwide and becomes more and more common due to the demographic change in developed countries. The high prevalence and severe personal burden for affected patients generate the urge to gain a deeper understanding of the disease entity and to optimize patient care. For both aspects, we analyzed specific interleukin (IL) levels in sera of nAMD patients several years ago [1]. Herein, we would like to report on our follow-up analyses of that cohort. As previously identified elevated serum levels of specific interleukins in nAMD patients and now evaluated whether these interleukins correlate with clinical parameters over five years. Serum interleukin levels (IL-1α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12, IL-13, IL-17, IL-23, and TNFα) do not correlate with the need for intravitreal injections, visual acuity, or central retinal thickness in a follow-up period of five years.

Our current analyses aimed at determining whether these IL levels are associated with different disease progressions. Thus, we retrospectively evaluated clinical data of our patient collective over 5 years and we were able to generate complete follow-up datasets of 24 patients (Table 1). Endpoints of our analyses included a number of intravitreal injections (IVI) over the 5 years, change in best-corrected visual acuity (BCVA), and change in central retinal thickness (CRT). A partial correlation between the clinical data and the serum levels (IBM SPSS version 27.0) was done and results were visualized using a heatmap (GraphPad Prism version 9.0). Confounding variables were age and sex as they impact the clinical and laboratory values.

Results are displayed in Fig. 1. It can be seen that serum levels of the analyzed interleukins do correspond to neither

---

**Key messages**
- As neovascular age-related macular degeneration (nAMD) has varying interindividual disease courses, biomarkers to identify high-risk patients would be of clinical use
- We previously identified elevated serum levels of specific interleukins in nAMD patients and now evaluated whether these interleukins correlate with clinical parameters over five years
- Serum interleukin levels (IL-1α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12, IL-13, IL-17, IL-23, and TNFα) do not correlate with the need for intravitreal injections, visual acuity, or central retinal thickness in a follow-up period of five years

---

Michelle Prasuhn
michelle.prasuhn@uksh.de
1 Department of Ophthalmology, University Hospital Schleswig-Holstein, University of Lübeck, Ratzeburger Allee 160, 23538 Lübeck, Germany
the number of IVIs needed, the change in BCVA, nor CRT changes.

Patients with nAMD regularly receive IVIs with anti-vascular endothelial growth factor therapy (anti-VEGF). Even though adverse events are rare, endophthalmitis and severe vision loss or even blindness can occur. Additionally, the regular visit rate is a high burden for elderly patients not only financially and socially but also psychologically. A wide variability concerning interindividual disease progression in nAMD causes several patients to be visited too frequently or not frequently enough and therefore to be over- or undertreated. Consequently, there is a high need for markers that allow us to identify patients who need to be followed up more regularly or who can gain more individual freedom by expanding clinical visit intervals.

Undoubtedly, the relevance to identify specific biomarkers like interleukins is of high interest to the research community, as many study groups started different attempts in various study designs.

More and more evidence underlines that immunological processes play an important role in the pathogenesis of nAMD [2–4]. Therefore, and having our previous results in mind, we found our approach to be promising to gain more insights into the disease current in connection with inflammatory changes. Our retrospective analyses were not able to detect correlations between specific interleukins and our clinical parameters. However, as reported in our previous manuscript, altered interleukin levels are present in sera of nAMD patients, so longitudinal prospective studies with larger cohorts are still a reasonable approach to look at this issue more in detail. The clinical course is one of the most important questions to address, as nAMD lacks specific and easily available prognostic markers. This could help us in clinical routine to identify patients who need to be followed up more regularly, as nAMD shows highly variable interindividual courses.

Acknowledgements We thank Prof. Dr. Salvatore Grisanti for giving us the opportunity to conduct this study in his clinic. We thank Caroline Hillers for reviewing medical records of patients.

Funding Open Access funding enabled and organized by Projekt DEAL.

Declarations

Ethical approval All procedures performed in studies involving human participants were in accordance with the ethical standards of the (place name of institution and/or national research committee) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent Informed consent was obtained from all individual participants included in the study.

Conflict of interest The authors declare no competing interests.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Nassar K, Grisanti S, Elfar E et al (2015) Serum cytokines as biomarkers for age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 253:699–704. https://doi.org/10.1007/s00417-014-2738-8
2. Ulhaq ZS, Soraya GV (2021) Roles of IL-8 -251A/T and +781C/T polymorphisms, IL-8 level, and the risk of age-related macular degeneration. Arch Soc Esp Oftalmol (Engl Ed) 96:476–487. https://doi.org/10.1016/j.oftale.2020.02.017

3. Sato T, Enoki T, Karasawa Y et al (2021) Inflammatory factors of macular atrophy in eyes with neovascular age-related macular degeneration treated with aflibercept. Front Immunol 12:738521. https://doi.org/10.3389/fimmu.2021.738521

4. Adamus G (2017) Can innate and autoimmune reactivity forecast early and advance stages of age-related macular degeneration? Autoimmun Rev 16:231–236. https://doi.org/10.1016/j.autrev.2017.01.005

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.